Sphingolipid Modulation: A Strategy for Cancer Therapy

ISSN: 1875-5992 (Online)
ISSN: 1871-5206 (Print)


Volume 16, 12 Issues, 2016


Download PDF Flyer




Anti-Cancer Agents in Medicinal Chemistry

Formerly: Current Medicinal Chemistry - Anti-Cancer Agents

This journal supports open access

Aims & ScopeAbstracted/Indexed in

Ranking and Category:
  • 27th of 59 in Chemistry, Medicinal

Submit Abstracts Online Submit Manuscripts Online

Editor-in-Chief:
Michelle Prudhomme
Universite Blaise Pascal - C.N.R.S
Aubiere Cedex
France


View Full Editorial Board

Subscribe Purchase Articles Order Reprints

Current: 2.722
5 - Year: 2.849

Sphingolipid Modulation: A Strategy for Cancer Therapy



Anti-Cancer Agents in Medicinal Chemistry, 12(4): 285-302.

Author(s): Antonio Delgado, Gemma Fabrias, Carmen Bedia, Josefina Casas and Jose Luis Abad.

Affiliation: Spanish National Research Council (Consejo Superior de Investigaciones Cientificas, CSIC), Research Unit on Bioactive Molecules (RUBAM); Departament de Quimica Biomedica; Institut de Quimica Avançada de Catalunya (IQAC); Jordi Girona 18-26, 08034 Barcelona, Spain.

Abstract

Sphingolipids are membrane lipids that play important roles in the regulation of cell functions and homeostasis. Alterations in their metabolism have been associated with several pathologies. For this reason, therapeutic strategies based on the design of small molecules to restore sphingolipid levels to their physiological condition have rapidly emerged. In addition, some of these new chemical entities, even if they fail to succeed along the pipeline, can become valuable pharmacological tools for the study of sphingolipid function. Implications of altered sphingolipid metabolism in cancer progression have allowed the identification of new targets for the development of potential anticancer agents. Based on these premises, this review is focused on the most recent achievements in the field, with special attention to the development of small molecules, mainly enzyme inhibitors, able to disrupt some of the key sphingolipid metabolic pathways implicated in cancer progression. On the other hand, metabolic dysregulation can also be modulated by the use of sphingolipid analogs, which can alter the sphingolipid balance driving cells to death or survival and thus becoming useful candidates for subsequent drug development.

Keywords:

Sphingolipids, Enzyme inhibitors, Analogs, Modulation, Metabolism, dhCer, cyclopropane, Cer-recognizing factors, denocarcinoma .



Purchase Online Order Reprints Order Eprints Rights and Permissions




Article Details

Volume: 12
Issue Number: 4
First Page: 285
Last Page: 302
Page Count: 18
DOI: 10.2174/187152012800228643
Price: $58
Advertisement

Related Journals




Webmaster Contact: urooj@benthamscience.org Copyright © 2016 Bentham Science